Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  MorphoSys    MOR   DE0006632003

MORPHOSYS

(MOR)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/14/2019 | 11:10am EDT

DGAP Voting Rights Announcement: MorphoSys AG
MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

14.05.2019 / 17:05
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: MorphoSys AG
Street: Semmelweisstr. 7
Postal code: 82152
City: Planegg
Germany
Legal Entity Identifier (LEI): 529900493806K77LRE72

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
X Other reason:
Voluntary group notification with threshold triggered on advisor level

3. Details of person subject to the notification obligation
Legal entity: FMR LLC
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
 

5. Date on which threshold was crossed or reached:
10 May 2019

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 8.94 % 0.00 % 8.94 % 31,839,572
Previous notification 8.95 % 0.00 % 8.95 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE000663203 2,847,109 % 8.94 %
Total 2,847,109 8.94 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
%
    Total %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
FMR LLC % % %
Fidelity Management & Research Company 5.94 % % 5.94 %
 
FMR LLC % % %
FIAM Holdings LLC % % %
Fidelity Institutional Asset Management Trust Company % % %
 
FMR LLC % % %
FIAM Holdings LLC % % %
FIAM LLC % % %
 
FMR LLC % % %
Fidelity Advisory Holdings LLC % % %
Strategic Advisers LLC. % % %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
13 May 2019



14.05.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Internet: www.morphosys.com

 
End of News DGAP News Service

810909  14.05.2019 

fncls.ssp?fn=show_t_gif&application_id=810909&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS
09/19Animal health sector aims to emulate Zoetis biotech leap
RE
09/19Biotech is going to the dogs - and big profits await
RE
09/17MORPHOSYS : to Present at Upcoming Investor Conferences
PU
09/17MORPHOSYS : to Present at Upcoming Investor Conferences
EQ
09/17MORPHOSYS : Licensee Janssen Submits Biologics License Application to U.S. FDA o..
AQ
09/16MORPHOSYS : Licensee Janssen Submits Biologics License Application to U.S. FDA o..
PU
09/16MORPHOSYS : Licensee Janssen Submits Biologics License Application to U.S. FDA o..
EQ
09/12MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
09/10MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
09/06MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
More news
Financials (EUR)
Sales 2019 69,9 M
EBIT 2019 -101 M
Net income 2019 -94,1 M
Finance 2019 351 M
Yield 2019 -
P/E ratio 2019 -33,9x
P/E ratio 2020 -35,1x
EV / Sales2019 42,8x
EV / Sales2020 26,2x
Capitalization 3 342 M
Chart MORPHOSYS
Duration : Period :
MorphoSys Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MORPHOSYS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 119,92  €
Last Close Price 105,60  €
Spread / Highest target 42,0%
Spread / Average Target 13,6%
Spread / Lowest Target -23,3%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Marc Cluzel Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Wendy S. Johnson Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS18.94%3 677
IQVIA HOLDINGS INC33.94%30 481
LONZA GROUP35.89%25 846
CELLTRION, INC.--.--%18 845
INCYTE CORPORATION22.85%17 466
EXACT SCIENCES CORPORATION64.77%13 463